Insulin Resistance Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Insulin Resistance pipeline constitutes 8+ key companies continuously working towards developing 10+ Insulin Resistance treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Insulin Resistance Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Insulin Resistance Market.

The Insulin Resistance Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Insulin Resistance Pipeline Report: https://www.delveinsight.com/sample-request/insulin-resistance-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Insulin Resistance treatment therapies with a considerable amount of success over the years.
• Insulin Resistance companies working in the treatment market are Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Eli Lilly and Company, Genfit, Novartis, Daiichi Sankyo, Inc., and others, are developing therapies for the Insulin Resistance treatment
• Emerging Insulin Resistance therapies in the different phases of clinical trials are- CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS® (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others are expected to have a significant impact on the Insulin Resistance market in the coming years.
• In September 2025, Innovent Biologics, Inc. (HKEX: 01801), a prominent biopharmaceutical company focused on developing, manufacturing, and commercializing therapies for oncology, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major conditions, announced that China's National Medical Products Administration (NMPA) has approved mazdutide. This first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist is indicated for glycemic control in adults with type 2 diabetes (T2D). Mazdutide is the world's first dual GCG/GLP-1 receptor agonist approved for this purpose and is expected to enhance comprehensive disease management in China, offering improvements in glycemic control, weight reduction, and hepato-cardio-renal metabolic health.
• In May 2025, A study published in *Nature* titled, "Acute regulation of murine adipose tissue lipolysis and insulin resistance by the TGFβ superfamily protein GDF3," explored the role of Growth Differentiation Factor 3 (GDF3) in mature adipocyte function. The research revealed that inducible loss of GDF3 activity in obese adult mice resulted in decreased lipolysis, enhanced glucose tolerance, and reduced fluctuations in blood glucose levels.
• In June 2024, OrsoBio, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for obesity and related metabolic disorders, announced new findings on its liver-targeted mitochondrial protonophore, TLC-6740, at the 84th Scientific Sessions of the American Diabetes Association. The company shared three abstracts highlighting data that demonstrate the safety and early efficacy of TLC-6740 in healthy volunteers, along with preclinical results showing weight reduction through enhanced energy expenditure and improved glycemic control in mouse models. These benefits were observed with TLC-6740 as a standalone treatment and in combination with the selective ACC2 inhibitor TLC-3595 and a GLP-1 receptor agonist.

Insulin Resistance Overview
Insulin resistance is a condition in which the body's cells do not respond effectively to insulin, a hormone that helps move glucose (sugar) from the blood into cells for energy. As a result, the pancreas produces more insulin to compensate, leading to higher insulin levels in the blood. Over time, this can cause elevated blood sugar levels and increase the risk of developing type 2 diabetes, obesity, and cardiovascular diseases.

Get a Free Sample PDF Report to know more about Insulin Resistance Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/insulin-resistance-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Insulin Resistance Drugs Under Different Phases of Clinical Development Include:
• CRB-913: Corbus Pharmaceuticals Holdings, Inc.
• Ziftomenib: Kura Oncology, Inc
• SCO-240: SCOHIA Pharma Inc
• ATR-258: Atrogi
• ID110521156: YUNOVIA CO.,LTD.
• Visepegenatide (PB-119): PegBio
• Retatrutide: Eli Lilly and Company
• TNX-1900: Tonix Pharmaceuticals
• Steglatro: Pfizer
• TLC-3595: OrsoBio
• Ladarixin: Dompe Farmaceutici
• Avandia: GlaxoSmithKline
• Triflusal (DCI): J. Uriach and Company
• MICARDIS® (telmisartan): Boehringer Ingelheim
• U-500 insulin: Eli Lilly and Company
• Vildagliptin: Novartis
• GFT505: Genfit
• Nateglinide: Novartis
• Olmesartan medoxomil: Daiichi Sankyo, Inc.

Insulin Resistance Route of Administration
Insulin Resistance pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous

Insulin Resistance Molecule Type
Insulin Resistance Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Insulin Resistance Pipeline Therapeutics Assessment
• Insulin Resistance Assessment by Product Type
• Insulin Resistance By Stage and Product Type
• Insulin Resistance Assessment by Route of Administration
• Insulin Resistance By Stage and Route of Administration
• Insulin Resistance Assessment by Molecule Type
• Insulin Resistance by Stage and Molecule Type

DelveInsight's Insulin Resistance Report covers around 10+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Insulin Resistance product details are provided in the report. Download the Insulin Resistance pipeline report to learn more about the emerging Insulin Resistance therapies
https://www.delveinsight.com/sample-request/insulin-resistance-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Insulin Resistance Therapeutics Market include:
Key companies developing therapies for Insulin Resistance are - Exscien Corp, Glycomantra Inc, Hanmi Pharmaceuticals Co Ltd, NorthSea Therapeutics BV, Amolyt Pharma, Amryt Pharma Plc, CohBar Inc, Lixte Biotechnology Holdings Inc, The Healthy Aging Co, Trigemina Inc, and others.

Insulin Resistance Pipeline Analysis:
The Insulin Resistance pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Insulin Resistance with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Insulin Resistance Treatment.
• Insulin Resistance key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Insulin Resistance Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Insulin Resistance market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Insulin Resistance drugs and therapies
https://www.delveinsight.com/sample-request/insulin-resistance-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Insulin Resistance Pipeline Market Drivers
• Increasing prevalence of chronic diseases, particularly diabetes, government initiatives to motivate research in diabetes, aging population and increasing obesity prevalence in developing countries are some of the important factors that are fueling the Insulin Resistance Market.

Insulin Resistance Pipeline Market Barriers
• However, less clinical information on insulin resistance has restricted the scope of drug development, limited drugs approved by the FDA are available in the market for the treatment of insulin resistance and other factors are creating obstacles in the Insulin Resistance Market growth.

Scope of Insulin Resistance Pipeline Drug Insight
• Coverage: Global
• Key Insulin Resistance Companies: Corbus Pharmaceuticals Holdings, Inc., Kura Oncology, Inc, SCOHIA Pharma Inc, Atrogi, YUNOVIA CO.,LTD., PegBio, Eli Lilly and Company, Tonix Pharma, Pfizer, OrsoBio, Dompe Farmaceutici, GlaxoSmithKline, J. Uriach and Company, Boehringer Ingelheim, Eli Lilly and Company, Genfit, Novartis, Daiichi Sankyo, Inc., and others
• Key Insulin Resistance Therapies: CRB-913, Ziftomenib, SCO-240, ATR-258, ID110521156, Visepegenatide (PB-119), Retatrutide, TNX-1900, Steglatro, TLC-3595, Ladarixin, Avandia, Triflusal (DCI), MICARDIS® (telmisartan), U-500 insulin, Vildagliptin, GFT505, Nateglinide, Olmesartan medoxomil, and others
• Insulin Resistance Therapeutic Assessment: Insulin Resistance current marketed and Insulin Resistance emerging therapies
• Insulin Resistance Market Dynamics: Insulin Resistance market drivers and Insulin Resistance market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.